Search for: All records

We present results of a search for spin-independent dark matter-nucleus interactions in a $1{\mathrm{cm}}^2$by 1 mm thick (0.233 g) high-resolution silicon athermal phonon detector operated above ground. For interactions in the substrate, this detector achieves an rms baseline energy resolution of $361.5\left(4\right)\mathrm{m}\mathrm{eV}$(statistical error), the best for any athermal phonon detector to date. With an exposure of $0.233\mathrm{g}\times 12$hours, we place the most stringent constraints on dark matter masses between 44 and $87\mathrm{M}\mathrm{eV}/{\mathrm{c}}^2$, with the lowest unexplored cross section of $4\times {10}^{-32}{\mathrm{c}\mathrm{m}}^2$at $87\mathrm{M}\mathrm{eV}/{\mathrm{c}}^2$. We employ a conservative salting technique to reach the lowest dark matter mass ever probed via direct detection experiment. This constraint is enabled by two-channel rejection of low energy backgrounds that are coupled to individual sensors. 

Background: Glioblastoma (GBM) is an aggressive brain tumor giving a poor prognosis with the current treatment options. The advent of chimeric antigen receptor (CAR) T-cell therapy revolutionized the field of immunotherapy and has provided a new set of therapeutic options for refractory blood cancers. In an effort to apply this therapeutic approach to solid tumors, various immune cell types and CAR constructs are being studied. Notably, macrophages have recently emerged as potential candidates for targeting solid tumors, attributed to their inherent tumorinfiltrating capacity and abundant presence in the tumor microenvironment. Materials and methods: In this study, we developed a chemically defined differentiation protocol to generate macrophages from human pluripotent stem cells (hPSCs). A GBM-specific CAR was genetically incorporated into hPSCs to generate CAR hPSC-derived macrophages. Results: The CAR hPSC-derived macrophages exhibited potent anticancer activity against GBM cells in vitro. Conclusion: Our findings demonstrate the feasibility of generating functional CAR-macrophages from hPSCs for adoptive immunotherapy, thereby opening new avenues for the treatment of solid tumors, particularly GBM.